The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders

M. Brittany Johnson, Ada D. Young and Ian Marriott*

Department of Biological Sciences, The University of North Carolina at Charlotte, Charlotte, NC, USA

The inflammatory responses of resident central nervous system (CNS) cells are now known to play a critical role in the initiation and progression of an array of infectious and sterile neuroinflammatory disorders such as meningitis, encephalitis, Parkinson’s disease, Alzheimer’s disease and multiple sclerosis (MS). Regulating glial inflammatory responses in a timely manner is therefore critical in preserving normal CNS functions. The neuropeptide substance P is produced at high levels within the CNS and its selective receptor, the neurokinin 1 receptor (NK-1R), is abundantly expressed by neurons and is present on glial cell types including microglia and astrocytes. In addition to its functions as a neurotransmitter in the perception of pain and its essential role in gut motility, this tachykinin is widely recognized to exacerbate inflammation at peripheral sites including the skin, gastrointestinal tract and the lungs. Recently, a number of studies have identified a role for substance P and NK-1R interactions in neuroinflammation and described the ability of this neuropeptide to alter the immune functions of activated microglia and astrocytes. In this review article, we describe the expression of substance P and its receptor by resident CNS cells, and we discuss the ability of this neuropeptide to exacerbate the inflammatory responses of glia and immune cells that are recruited to the brain during neurodegenerative diseases. In addition, we discuss the available data indicating that the NK-1R-mediated augmentation of such responses appears to be detrimental during microbial infection and some sterile neurodegenerative disorders, and propose the repurposed use of NK-1R antagonists, of a type that are currently approved as anti-emetic and anti-anxiolytic agents, as an adjunct therapy to ameliorate the inflammatory CNS damage in these conditions.

Keywords: substance P, neuroinflammation, neuropeptide, neurokinin-1 receptor, tachykinin, microglia, astrocytes

Substance P is a member of the tachykinin family of neuropeptides that share common pharmacological properties and a conserved carboxyl-terminal sequence (Phe-X-Gly-Leu-Met-NH2, X hydrophobic or aromatic; Harrison and Geppetti, 2001). The carboxyl-terminal sequence is required for interaction with tachykinin receptors and cellular activation, while the distinct amino-terminal confers receptor subtype specificity (Gerard et al., 1991). The tachykinins are expressed broadly throughout the nervous and immune systems (Harrison and Geppetti, 2001;
Tachykinins were originally named for their ability to stimulate contraction of intestinal muscle in the seminal work by V Euler and Gaddum (1931) in which “preparation P”, later renamed substance P, isolated from horse intestine and brain induced isolated rabbit jejunum contraction. It is now appreciated that substance P and its receptor are found in high quantities throughout the CNS. Substance P immunoreactivity was observed in the CNS as early as the mid-1970s (Hökfelt et al., 1975; Cuello and Kanazawa, 1978; Ljungdahl et al., 1978a,b; Cuello et al., 1979) and neuroanatomical analysis of substance P distribution in the rat CNS revealed the highest levels in the substantia nigra and the medial amygdaloid nucleus of the brain, and in the superficial dorsal horn of the spinal cord (Ribeiro-da-Silva and Hökfelt, 2000). The presence of substance P within the primary sensory neurons of the brainstem, cranial nerve nuclei, and spinal cord dorsal horn (Cuello and Kanazawa, 1978; Cuello et al., 1979, 1993; Douglas and Leeman, 2011) is consistent with its role as a sensory neurotransmitter important for the perception of pain (Douglas and Leeman, 2011).

However, substance P is found in many other regions of the brain including the hippocampus, cortex, basal ganglia and hypothalamus (Ebner and Singewald, 2006), and can produce effects throughout the CNS. Furthermore, this tachykinin is also broadly distributed throughout the peripheral nervous system and enteric nervous system, and can be expressed by cells of the immune system. Specifically, substance P can be expressed by peripheral leukocytes including lymphocytes and monocytes/macrophages (Bost et al., 1992; Bost, 1995; Ho et al., 1997; Lai et al., 1998; Chernova et al., 2009).

NK-1R is a G-protein coupled receptor and has the highest affinity for substance P over other tachykinin receptors and is found as two isoforms; a full-length form (407 amino acids) and a truncated form (311 amino acids; Fong et al., 1992; Baker et al., 2003). The truncated form of NK-1R binds substance P with 10-fold lower affinity than the long form (Douglas and Leeman, 2011). Substance P binding to full-length NK-1R stimulates phosphorylation of the C-terminus via G-protein receptor kinases and protein kinase C to activate members of the mitogen-activated protein kinase (MAPK) cascade, including
extracellular signal-regulated kinases 1 and 2, and p38 MAPK (as reviewed in Steinhoff et al., 2014). Importantly, in immune cells such as macrophages, activation of MAPK cascades precipitates activation of NF-kB, the master regulator of immune mediator production (Sun et al., 2008). Hence, through activation of NF-kB, substance P can augment inflammation by stimulating the production of proinflammatory cytokines (Bost, 2004a).

In contrast, the truncated NK-1R lacks the majority of the C-terminus and is not phosphorylated following substance P binding. Accordingly, signaling via this truncated form does not result in NF-kB activation, and fails to elicit cellular effects including desensitization, endocytosis, endosomal signaling changes and production of inflammatory chemokines such as IL-8 (DeFea et al., 2000; Lai et al., 2008). However, the truncated NK-1R form may have biological functions beyond serving as a decoy receptor, and has been suggested to provide or augment a persistent growth stimulus to cancer cells (Gillespie et al., 2011).

Substance P mediates numerous and cell-type specific effects throughout the body due to the broad expression of NK-1R in many cell types and tissues. Like substance P, NK-1R expression is widely distributed throughout the CNS as determined by autoradiography, in situ hybridization and immunohistochemical approaches (Mantyh et al., 1984, 1989; Nakaya et al., 1994; Caberlotto et al., 2003). NK-1R mRNA is found in the olfactory bulb, cerebral cortex, medulla oblongata and spinal cord in mice (Andoh et al., 1996). Initial studies of human brain revealed high levels of NK-1R expression in the locus coeruleus and ventral striatum, moderate expression in the cerebral cortex, hippocampus and amygdaloid nuclei, and only low levels in the cerebellum and thalamus (Caberlotto et al., 2003). Further studies, using positron emission tomographic analysis of healthy human males using a high-affinity ¹⁸F labeled-NK-1R antagonist, suggested that the highest levels of cellular NK-1R expression normally occur in the caudate and the putamen, regions of the brain in close proximity to the amygdaloid nucleus (Hietala et al., 2005). The constitutive expression and anatomical location of this neuropeptide and its receptor in the limbic system of the healthy brain suggest that substance P/NK-1R interactions play an integral role in complex CNS processing, and the neurotransmitter/neuromodulatory functions of this tachykinin have recently been reviewed elsewhere (Garcia-Recio and Gascón, 2015).

It is noteworthy that there has been considerable recent interest in defining the location of NK-1R expressing cells with the recognition that substance P may not act as a classical neurotransmitter. Rather, there are anatomical mismatches between substance P release sites and responsive cells (Liu et al., 1994; Nakaya et al., 1994). Liu et al. (1994) determined that many substance P receptors had non-synaptic localizations within the rat CNS. The ability of substance P to diffuse and act upon distant cells suggests that this neuropeptide could have endocrine characteristics within the CNS and beyond. The relevance of this is underscored by the fact that numerous non-neuronal cell types, such as smooth muscle cells, fibroblasts, keratinocytes and endothelial cells, functionally express NK-1R. Importantly, glial cells with immune functions and leukocytes recruited to the CNS also express NK-1R, either constitutively or following activation (Schaffer et al., 1998), and so may be susceptible to the pro-inflammatory actions of this neuropeptide. However, it should be noted that the cellular expression of the truncated NK-1R form can also be dynamic (Vilisaar et al., 2015), and few studies have distinguished between the full length and truncated form of this receptor.

**SUBSTANCE P PROMOTES LEUKOCYTE RECRUITMENT AND ACTIVATION**

While the CNS is extensively protected by the blood-brain barrier, inflammation within the brain leads to the infiltration of peripheral macrophages, dendritic cells, T cells and other immune responders (Hickey, 1999; Whitney et al., 2009), and it is well recognized that there is extensive crosstalk between the nervous system and the immune system. Trauma and infections of the CNS are characterized by high levels of inflammatory mediators such as cytokines (Ziebell and Morganti-Kossmann, 2010), and immunomodulatory neuropeptides including substance P can affect the release of cytokines by immune cells (Lee et al., 1994; Ho et al., 1996). In turn, inflammatory cytokines can regulate the release of substance P and expression of NK-1R by leukocytes, further sensitizing these cells to the effects of substance P in a positive feedback loop-like manner (Marriott and Bost, 2000; Blum et al., 2001, 2008; Weinstock et al., 2003a).

The interaction of substance P with NK-1R triggers neurogenic inflammation and directly augments inflammatory processes in the lung, gut, skin and other peripheral organs (Steinhoff et al., 2014). Neurogenic inflammation is characterized by vasodilation and increased vascular permeability leading to increased immune cell infiltration (Brown and Neher, 2010). Substance P promotes inflammation in at least three ways as recently discussed by Corrigan et al. (2016). First, substance P elicits vasodilation and increases vascular permeability. Second, this neuropeptide can facilitate leukocyte extravasation by inducing the expression of adhesion molecules necessary for immune cell adherence to endothelial cells, and by subsequently promoting their migration to the site of injury or infection. Third, substance P can act directly on resident and/or infiltrating cells to augment their immune functions.

Early reports identified the expression of substance P and/or NK-1R by peripheral human lymphocytes and monocytes/macrophages (Bost et al., 1992; Ho et al., 1997; Lai et al., 1998). Since these studies, natural killer cells, dendritic cells, mast cells and neutrophils have been added to the list and have been shown to either express NK-1R or respond to substance P in an NK-1R-dependent manner (Marriott and Bost, 2001a; O’Connor et al., 2004). Accordingly, during an immune challenge, substance P produced by immune and non-immune cell types can function as a potent chemotactrant and promote the inflammatory responses of a diverse range of cells including macrophages,
dendritic cells, lymphocytes and eosinophils (O’Connor et al., 2004). However, it should be noted that the mechanisms underlying the actions of substance P on eosinophils are more controversial as its effects have been reported to occur in a receptor-independent manner, either via the N-terminus of substance P or via interactions with epithelial cells (Kroegel et al., 1990).

Substance P has been shown to also stimulate or augment the production of inflammatory cytokines by monocytes/macrophages, T lymphocytes and mast cells, and can promote the release of inflammatory mediator-containing granules of neutrophils, mast cells and eosinophils (Bill et al., 1979; Shanahan et al., 1985; Lotz et al., 1988; Serra et al., 1988; Kroegel et al., 1990; Calvo et al., 1992; Ho et al., 1996; Marriott and Bost, 2001b). In addition, this neuropeptide can also inhibit the production of the immunosuppressive cytokine TGF-β1 by activated macrophages (Marriott and Bost, 1998) providing another mechanism by which this tachykinin can foster an inflammatory environment. Furthermore, substance P has been reported to stimulate T-lymphocyte proliferation and natural killer cell activity, and substance P may also serve as a B-lymphocyte differentiation cofactor and augment immunoglobulin secretion (Croitoru et al., 1990; Pascual and Bost, 1990; Pascual et al., 1991a,b, 1992; Bost and Pascual, 1992; Covas et al., 1994). As such, these studies indicate that this neuropeptide has the potential to exacerbate both acute and chronic inflammatory immune responses associated with the recruitment of immune cells to the CNS.

Due to the dynamic crosstalk between the nervous system and the immune system, it is perhaps not surprising that the expression of both substance P and its receptor are regulated by immune responses. The potent inflammatory mediator IL-12, the related cytokine IL-23 and IL-18, can all induce substance P production and NK-1R expression by murine macrophages and T-lymphocytes (Blum et al., 2001, 2008; Weinstock et al., 2003a; Arsenescu et al., 2005). In addition, a recent study has provided evidence for the reciprocal positive regulation of IL-23 and IL-17 pathways and NK-1R expression in human mononuclear cells (Vilisaar et al., 2015). The ability of IL-12/IL-23 cytokines and IL-18 to induce NK-1R expression can be explained due to the ability of both of these cytokines to elicit cellular effects via NF-kB activation (Weinstock et al., 2003a), and the fact that the promoter region of the NK-1R gene contains a binding site for this transcription factor (Takahashi et al., 1992). Similarly, other pro-inflammatory cytokines including IFN-γ and TNF-α can elevate NK-1R expression in macrophages, while this effect can also be achieved with the signature T-helper type 2 cytokine, IL-4 (Marriott and Bost, 2000).

In contrast, cytokines with anti-inflammatory functions, such as IL-10 and TGF-β, have been reported to reduce the expression of substance P and NK-1R in immune cells (Weinstock et al., 2003b; Blum et al., 2008). However, caution should be taken in designating the effects of pleiotropic cytokines such as TGF-β. While TGF-β is generally considered to be immunosuppressive, the presence of this cytokine in combination with inflammatory cytokines, such as IL-6, promotes the formation of proinflammatory TH17 T-cells (Bettelli et al., 2006). Furthermore, there is evidence that this cytokine can down-regulate NK-1R internalization by T-cells in a mouse model of inflammatory bowel disease, and can enhance signal transduction pathways used by effector T-cells to augment inflammatory cytokine production (Beinborn et al., 2010).

**SUBSTANCE P PROMOTES THE INFLAMMATORY IMMUNE RESPONSES OF RESIDENT CNS CELLS**

The brain has typically been characterized as a victim organ of infiltrating leukocytes, but it is increasingly appreciated that resident glial cells play an essential role in the initiation and progression of immune responses within the CNS. While, early studies reported substance P immunoreactivity in cells and tissues isolated from the CNS (Michel et al., 1986; Kostyk et al., 1989), it is now recognized that non-neuronal CNS cells can express both substance P and its receptor, either constitutively or following exposure to inflammatory/damaging stimuli, much like peripheral immune cells. Cortical and white matter astrocytes express substance P and NK-1R (Michel et al., 1986; Torrens et al., 1989; Beaujouan et al., 1991; Marriott and Wilkin, 1993), and this receptor has also been detected in human spinal cord astrocytes (Palma et al., 1997). Like leukocytes, the expression of substance P and its receptor by astrocytes is influenced by inflammatory mediators. For example, levels of NK-1R expressed by a human astrocytic cell line and rat primary astrocytes are elevated in response to the potent inflammatory cytokine IL-1β, consistent with previous observations that substance P binding sites are highly expressed following neuronal injury (Guo et al., 2004).

While the expression of substance P receptors by neurons, cerebral endothelial cells, and astrocytes is well established, the expression of authentic substance P receptors on microglia is more controversial. Luber-Narod et al. (1994) reported a lack of detectable binding sites for radiolabeled substance P on microglia, either at rest or following challenge with bacterial lipopolysaccharide. Similarly, another study failed to detect in vivo NK-1R expression by rat microglia following ischemic brain injury as determined by in situ hybridization and immunohistochemical staining approaches (Stumm et al., 2001). In contrast, our own studies indicate that neonatal mouse microglia express mRNA encoding NK-1R and we have confirmed the presence of this receptor protein in this cell type by Western blot analysis and flow cytometry (Rasley et al., 2002b). Likewise, NK-1R has been specifically detected in human fetal brain microglia and rat spinal microglia (Lai et al., 2000; Bradesi et al., 2009).

Importantly, the interaction of substance P with NK-1R appears to promote inflammatory immune responses by glia in a similar manner to its effects on peripheral leukocytes. Substance P activates the key inflammatory regulator NF-κB in human astrocytoma cells (Lieb et al., 1997), and can elicit the production of a number of inflammatory cytokines, including IL-6, IL-8 and granulocyte macrophage colony-stimulating factor (GM-CSF), and reactive oxygen intermediates by these cells.
and primary human embryonic and spinal astrocytes (Lieb et al., 1997; Palma et al., 1997; Palma and Manzini, 1998). Similarly, we have shown that this neuropeptide induces the nuclear translocation of the RelA subunit of NF-kB (Rasley et al., 2002b) in primary murine microglia, while Zhu et al. (2014) have recently shown that exposure to substance P, in combination with histamine, results in the production of reactive oxygen species and the release of IL-6 and TNF-α by these cells. Since microglia and astrocytes are susceptible to the pro-inflammatory effects of substance P, this neuropeptide appears to be capable of exacerbating the immune responses of both resident CNS cells and recruited leukocytes in CNS damage or disease.

**EVIDENCE FOR THE INVOLVEMENT OF SUBSTANCE P IN CNS DISORDERS**

Given that both resident glia and infiltrating leukocytes can express substance P and its receptor, either constitutively or following exposure to immune mediators, and that substance P is present at high levels throughout the CNS, it is perhaps not surprising that this neuropeptide has been implicated in the pathogenesis of a number of inflammatory CNS disorders.

It is well known that CNS trauma and infection are accompanied by widespread inflammation in the brain and resident glial cells, including astrocytes and microglia, play a key role in the initiation and propagation of this response (Corrigan et al., 2016). Although protected extensively by the blood-brain barrier, neuroinflammation leads to infiltration of peripheral macrophages, dendritic cells, T cells, and other immune responders (Hickey, 1999; Whitney et al., 2009). Activated glial cells secrete a plethora of pro-inflammatory mediators including PGE₂ (Rasley et al., 2002a, 2004b), IL-12 (Rasley et al., 2004a), IL-6, and TNF-α (Chauhan et al., 2009, 2010) resulting in the disruption of the blood-brain barrier thereby facilitating cellular infiltration (Hickey, 1999; Lossinsky and Shivers, 2004; Taupin, 2008; Whitney et al., 2009). Accordingly, the ability of substance P to induce vasodilation in the brain, promote the recruitment of immune cells, and augment the inflammatory responses of both infiltrating and resident cells, can contribute to the development of devastating conditions such as meningitis and encephalitis following infection (Maggi, 1995; O’Connor et al., 2004; Corrigan et al., 2016).

A compelling body of evidence now suggests that interactions between substance P and NK-1R exacerbate CNS inflammation during parasitic, viral and bacterial infections. Neurocysticercosis is a parasitic infection of the CNS caused by *Taenia solium* that results in seizures in patients due to the granulomatous host immune response to this pathogen. Analysis of biopsies from human neurocysticercosis patients has shown the presence of substance P positive cells adjacent to degenerating worms, and this neuropeptide is expressed in granulomas in murine models of neurocysticercosis (Robinson et al., 2002). Interestingly, administration of substance P into the rodent hippocampus can induce seizures, and levels of substance P correlate with granuloma formation and seizure activity in animal models of CNS helminth infection. Furthermore, substance P/NK-1R interactions are required for cytokine responses and seizures associated with neurocysticerosis granulomas (Garza et al., 2008, 2010). Human African trypanosomiasis also affects the CNS and substance P has similarly been implicated in the neuropathology of this protozoan parasite. Inhibition of substance P/NK-1R interactions using the non-peptide NK-1R antagonist RP-67580 reduces the inflammatory response and the reactive astrogliosis associated with *Trypanosoma brucei* infection of the CNS (Kennedy et al., 1997), further supporting a role for substance P/NK-1R interactions in neuroinflammation associated with eukaryotic parasite CNS infections.

Bacterial infections of the CNS are serious and often intractable conditions affecting the meninges and the brain parenchyma. During bacterial meningitis, increased cellularity and reactive astrogliosis are hallmarks of an active immune response within the CNS. Such responses indicate activation of resident astrocytes and the accumulation of cells at the site of bacterial challenge, either due to proliferation of glial cells including microglia, or the recruitment of peripheral leukocytes. Furthermore, the recruitment and/or activation of resident glial cells and infiltrating leukocytes are associated with high CNS levels of inflammatory mediators resulting in neurological dysfunction. Using mice deficient in the expression of NK-1R or the prophylactic administration of the NK-1R antagonist L703,606, we have demonstrated that substance P interactions with NK-1R are required for the increases in blood-brain barrier permeability, astrogliosis, increased CNS cellularity, and elevated numbers of microglia/macrophages associated with infection with the clinically relevant bacterial CNS pathogens *Streptococcus pneumoniae*, *Neisseria meningitidis* and *Borrelia burgdorferi* (Chauhan et al., 2008, 2011). Furthermore, in these studies we have shown that substance P/NK-1R interactions are involved in bacterially-induced demyelination and behavioral changes following infection with these disparate bacterial species. Importantly, the decreases in bacterial-induced CNS disease severity seen with NK-1R inhibition or deficiency were associated with diminished CNS production of key inflammatory mediators including IL-6 and TNF-α, and the prevention of infection-induced decreases in the level of the anti-inflammatory cytokine IL-10.

Interestingly, bacterial infection in these mouse models is associated with elevated levels of NK-1R expression in the brain and, specifically, by microglia and astrocytes (Chauhan et al., 2011). Such increases are particularly important since we have shown that substance P can significantly increase bacteria induced IL-6 production by microglia (Chauhan et al., 2008). Furthermore, this neuropeptide can augment microglial expression of the pro-inflammatory enzyme cyclooxygenase-2 and its product prostaglandin E₂, and elevate expression of the pro-inflammatory enzyme cyclooxygenase-2. Such increases are particularly important since we have shown that substance P can significantly increase bacteria induced IL-6 production by microglia (Chauhan et al., 2008). Furthermore, this neuropeptide can augment microglial expression of the pro-inflammatory enzyme cyclooxygenase-2 and its product prostaglandin E₂, and elevate expression of the prostaglandin receptors EP2 and EP4 to further potentiate inflammation (Rasley et al., 2004b). Together, these animal studies indicate a pivotal role for substance P in the initiation and progression of damaging neuroinflammation following bacterial infection of the CNS.
Similarly, intense CNS inflammation can occur following viral infection and a relationship between substance P and human immunodeficiency virus (HIV) infection has been suggested. Elevated levels of substance P have been observed in the serum of HIV infected patients and simian immunodeficiency virus-infected rhesus macaques (Douglas et al., 2001, 2008a,b; Lai et al., 2001; Vinet-Oliphant et al., 2010). Viral levels correlate with the amount of substance P released by immune cells and it has been suggested that this neuropeptide may facilitate viral replication by increasing the expression of receptors including CCR5 that are required for HIV infection of host cells (Bost, 2004a; Manak et al., 2010). In the CNS, human fetal brain cells have been shown to express NK-1R and interactions between this receptor and substance P appear to exacerbate HIV-1 infection (Schwartz et al., 2013).

Finally, substance P interactions with NK-1R have been associated with CNS disorders that are generally associated with sterile inflammation such as Alzheimer’s disease, Parkinson’s disease, multiple system atrophy (MSA) and multiple sclerosis (MS). However, it seems that this influence may center on the neuroprotective effects of this neuropeptide. Decreased levels of substance P have been reported in animal models of CNS motor disorders and in the brain tissue of postmortem Parkinson’s disease patients (Chen et al., 2004). Similarly, in Alzheimer’s disease, reduced levels of substance P are observed in the cortical regions of postmortem brain tissues and in patient cerebrospinal fluid (Quigley and Kowall, 1991; Kowall et al., 1993; Waters and Davis, 1997; Raffa, 1998). Furthermore, in MSA and Parkinson’s disease patients there is severe depletion of NK-1R expressing neurons in the ventrolateral medulla (Benarroch et al., 2003). But even this apparently benign role may have a darker side as substance P immunoreactive astrocytes have been identified in MS plaques (Kostyk et al., 1989), and a requirement for substance P/NK-1R interactions has been reported for the maintenance of chronic inflammation in experimental autoimmune encephalomyelitis (EAE) mouse models of MS (Reinke et al., 2006). Such a detrimental role is also supported by genome-wide linkage studies identifying the TAC1 gene encoding the substance P precursor protein as a possible MS susceptibility gene (Vandenbroeck et al., 2002; Cunningham et al., 2007).

Together, the available data indicate that interactions between substance P and NK-1R dictate the inflammatory response observed in diverse CNS infections or disorders. Additionally, the amount of substance P released by neurons and immune cells, along with the number of available receptors, determines the level of neuroinflammation, as greater release of substance P permits diffusion of this neuropeptide to more distal binding sites broadening its effect (Abbadie et al., 1996; Doyle and Hunt, 1999; Mantyh, 2002).

**SUBSTANCE P AS A DOUBLE-EDGED SWORD IN CNS IMMUNE RESPONSES**

An active immune response can be protective as well as detrimental in the CNS. While infiltrating leukocytes and resident glia play a role in limiting infection and trauma-associated damage, immune responses generated by these events may prove detrimental if not controlled and limited at the appropriate time (Douglas and Leeman, 2011). Indeed, multiple neurodegenerative disorders are associated with exacerbated immune responses by resident and recruited cells in the brain. Therefore, a delicate balance needs to be struck in order to limit the generation of damaging inflammation within the CNS.

For some bacterial and viral infections, substance P has been demonstrated to be necessary for clearance. For example, murine gammaherpesvirus 68 has been demonstrated to increase the expression of substance P and its receptor in mucosal and lymphoid organs. Importantly, NK-1R deficient mice show reduced CTL responses and IL-12 secretion, resulting in increased viral burden compared to wild type animals (Elsawa et al., 2003). Similarly, substance P/NK-1R interactions are required for resistance to Salmonella infection as demonstrated by the advanced salmonellosis and reduced survival rates in infected mice treated with an NK-1R antagonist (Kincy-Cain and Bost, 1996, 1997). Here again, substance P promotes IL-12 expression and this leads to IFN-γ production that drives the cell-mediated immunity required to clear this intracellular bacterial pathogen.

In contrast, this neuropeptide appears to contribute to disease pathology for some infectious agents. For example, substance P increases the bronchoconstriction and damaging cardiac inflammation following infection with respiratory syncytial virus and encephalomyocarditis virus, respectively (Bost, 2004b; Robinson et al., 2009). Likewise, substance P contributes to the severity of inflammation associated with *Trypanosoma brucei* infection and inflammation and granuloma size in a mouse model of *Taenia solium* cysticercosis (Kennedy et al., 1997; Garza et al., 2008, 2010).

As we discussed earlier, our data suggest that substance P similarly exacerbates damaging inflammation within the CNS to disparate bacterial pathogens. We determined that the absence of substance P/NK-1R interactions in substance P receptor deficient mice or prophylactic pharmacological NK-1R inhibition in wild type animals significantly reduces bacteria-induced neuroinflammation and resultant CNS damage (Chauhan et al., 2008, 2011). NK-1R null mice and mice treated with an NK-1R antagonist showed reduced inflammatory and maintained immunosuppressive cytokine production, as well as decreased astrogliosis, cellularity and demyelination following intracerebral administration of the Gram negative bacterial pathogens *N. meningitidis* and *B. burgdorferi*, or the Gram positive bacterium *S. pneumoniae* (Chauhan et al., 2008, 2011). These animal studies therefore indicate that substance P/NK-1R interactions are essential for the progression of damaging inflammation following bacterial CNS infection.

Targeting NK-1R also has the potential to ameliorate CNS disorders that are thought to involve sterile inflammation given the presence of substance P immunoreactive glia in MS plaques (Kostyk et al., 1989) and the reported ability of the non-peptide NK-1R antagonist SR140333 to attenuate chronic inflammation associated with mouse models of MS.
However, the benefit of inhibiting substance P/NK-1R interactions in other neurological disorders, including Alzheimer’s disease and Parkinson’s disease, is more equivocal due to the reported neuroprotective properties of this neuropeptide and/or its ability to stimulate non-amyloidogenic amyloid precursor protein processing (as discussed in Chen et al., 2004; Severini et al., 2016).

As such, the available data suggests that substance P contributes to neuroprotection during some degenerative CNS disorders and to beneficial cell-mediated host responses against viruses and intracellular bacteria facilitating pathogen clearance. Inhibiting substance P/NK-1R interactions in these conditions would likely compromise the protective effects of this neuropeptide and exacerbate disease severity. In contrast, NK-1R-mediated augmentation of glial and recruited leukocyte immune responses appears to be detrimental during extracellular bacterial and parasite infections of the CNS, and perhaps MS, by exacerbating neuroinflammation and neurological damage (as summarized in Table 1). Based on these studies, it appears that targeting substance P/NK-1R interactions might be a promising strategy to ameliorate the inflammatory CNS damage associated with such infectious agents and neurological disorders.

THE THERAPEUTIC POTENTIAL OF NK-1R ANTAGONISTS IN INFLAMMATORY CNS DISORDERS

The involvement of tachykinins in a wide range of pathological processes has made them an attractive target for therapeutic intervention, and the pharmaceutical industry has initiated the development of additional NK-1R antagonists (as discussed in Quartara and Altamura, 2006; Quartara et al., 2009). Many of these NK-1R antagonists have reached phase II and III clinical trials with one, aprepitant, currently approved by the United States Food and Drug Administration (Quartara and Altamura, 2006; Quartara et al., 2009; Di Fabio et al., 2013). The non-peptide NK-1R antagonist CP-96,345 has been reported to downregulate constitutive substance P mRNA expression in human mononuclear cells (Lai et al., 2002) and the ability of such NK-1R antagonists to treat a range of gastrointestinal, respiratory and urogenital, and sensory disorders has been explored. However, the utility of next generation NK-1R antagonists in the treatment of CNS conditions including nausea, addiction, pain, and depression, has been of particular interest due to their ability to cross the blood-brain barrier.

The first NK-1R antagonists were developed in the early 1990s, but most were not effective as analgesics and anti-depressants as they could not efficiently cross the blood-brain barrier. An exception to this rule was LY303870, which was shown to block rodent licking behavior in the late stages of persistent nociceptive activation with inhibition of ex vivo substance P binding to both peripheral and central NK-1R (Iyengar et al., 1997). Subsequently, an analysis of the pharmacokinetics of the non-peptide NK-1R antagonist ezlopitant in dogs revealed the presence of this compound and its two pharmacologically active metabolite compounds in cerebrospinal fluid following intravenous or oral administration, indicating its ability to cross the blood brain barrier (Reed-Hagen et al., 1999). Of the latest generation of NK-1R antagonists, aprepitant has been shown to cross the blood-brain barrier after oral administration using human positron emission tomography to demonstrate its ability to occupy NK-1R within the brain in an oral dose and plasma concentration dependent manner (Bergström et al., 2004). Similarly, the NK-1R antagonist casopitant, when radioactively labeled, has been demonstrated to be rapidly absorbed into the bloodstream and can subsequently be found within the brain (Ruhlmann and Herrstedt, 2009). This antagonist has completed phase II and III clinical trials and has similar success to aprepitant in the treatment of chemotherapy-induced nausea and vomiting (Ruhlmann and Herrstedt, 2009), but this drug has not yet received United States Food and Drug Administration approval.

The ability of NK-1R antagonists to cross the blood-brain barrier means that these agents have the potential for use in the treatment in wide range of CNS disorders. Indeed,

| CNS disorder                     | Model       | Organism     | Antagonist | Knockout | Effect                                                                 | Reference                  |
|----------------------------------|-------------|--------------|------------|----------|----------------------------------------------------------------------|----------------------------|
| Neurocysticercosis              | T. crassiceps | Mouse        | NK-1R      | Substance P | Lower granuloma volume. Less IL-1β, IL-6, TNF-α.                  | Garza et al. (2010)        |
| African trypanosomiasis         | T. brucei + diminazene | Mouse | RP-67580 |             | Reduced astrogliosis, clinical score, cellularity.                   | Kennedy et al. (1997)      |
| Bacterial meningitis            | S. pneumoniae | Mouse | L703,606 | NK-1R    | Reduced BBB permeability, astrogliosis, microgliosis, cellularity, demyelination, IL-6, TNF-α. More IL-10. | Chauhan et al. (2008) Chauhan et al. (2011) |
| Multiple sclerosis              | EAE         | Mouse        | SR 14033   | NK-1R    | Greater mobility. Decreased MOG specific T-cells.                    | Reinke et al. (2006)       |
|                                  |             |              | CP-96,345  |          | Less clinical and histological signs.                                | Nessler et al. (2006)      |
FIGURE 1 | Substance P-mediated exacerbation of neuroinflammatory damage following central nervous system (CNS) infection. Conserved microbial motifs are recognized by Toll-like receptor (TLR) and NOD-like receptors (NLR) pattern recognition receptors (PRR) expressed by perivascular macrophages, microglia and astrocytes leading to NF-kB activation and inflammatory and/or neurotoxic mediator production. Substance P (SP) released by neurons and perhaps activated glia acts on neurokinin-1 receptor (NK-1R) bearing CNS cells to augment NF-kB activation or function to enhance glial responses. Local inflammation promotes the recruitment of leukocytes to the site of infection that will, in turn, recognize microbial components and produce more pro-inflammatory and neurotoxic mediators. Infiltrating leukocytes such as monocytes/macrophages, dendritic cells and lymphocytes express NK-1R and so are similarly susceptible to the pro-inflammatory actions of substance P. Importantly, inflammatory cytokines can also augment the expression of PRR and NK-1R by glia and leukocytes, and can elevate local production of substance P. This positive feedback loop would be anticipated to increase the sensitivity of host cells to pathogen components and sensitize leukocytes and glia to this neuropeptide, thereby exacerbating inflammatory damage. Intervention with pharmaceutical NK-1R inhibitors capable of penetrating the blood-brain barrier would prevent substance P mediated exacerbation of glial and leukocyte inflammatory responses, and interrupt such a feedback loop.

aprepitant and its pro-drug fosaprepitant are currently employed as post-chemotherapy anti-emetic agents (Aapro et al., 2015). Likewise, casopitant has completed phase II and phase III trials and has similar success to aprepitant in the treatment of chemotherapy-induced nausea and vomiting (Ruhlmann and Herrstedt, 2009). In addition to use as an anti-emetic, there has been promising research that aprepitant and other NK-1R antagonists may have efficacy against other CNS disorders including depression. The NK-1R antagonist MK-869 has been shown to effectively suppress depressive behavior in guinea pigs, and both MK-869 and casopitant successfully completed phase II clinical trials to treat depression (Kramer et al., 1998; Ebner and Singewald, 2006; Di Fabio et al., 2013). However, it must be noted that MK-869 failed in a phase III trial to treat major depressive disorder (Keller et al., 2006).
There are also hopes that NK-1R antagonists may be valuable for the treatment of other CNS disorders as diverse as schizophrenia, panic attacks, Parkinson's disease, and MS. This hope stems from the promising effects of NK-1R antagonists capable of crossing the blood-brain barrier in animal models of such disorders (Table 1). For example, the NK-1R antagonist SR140333 has shown efficacy as a co-therapy with other anti-inflammatory agents in ameliorating myelin oligodendrocyte glycoprotein-induced EAE, a mouse model of MS (Reinke et al., 2006). Similarly, CP 96345, has also been demonstrated to reduce EAE severity, and this effect was associated with stabilization of the blood brain barrier as well as reduced T-helper type 1 immunity (Nessler et al., 2006).

Importantly, given a potential role for substance P/NK-1R interactions in damaging inflammatory responses within the CNS following infection, there is considerable interest in targeting this receptor to limit neuroinflammation and neurological sequelae associated with infectious agents (Table 1). For example, since direct hippocampal substance P administration elicits seizures in mice and an NK-1R antagonist has been shown to prevent seizure activity in a rodent model of helminth brain infection (Robinson et al., 2012), it is possible that blocking the actions of this neuropeptide may prove useful in neurocysticercosis patients. Furthermore, our own studies have shown that pharmacological targeting of NK-1R with the antagonist L703,606 can not only prevent the development of damaging inflammation due to streptococcal CNS infection when administered prophylactically, but can also reverse infection-associated gliosis and demyelination when delivered therapeutically without increasing CNS bacterial burden (Chauhan et al., 2011).

While further studies are clearly needed to define the specific mechanisms underlying the ability of substance P to augment CNS inflammation and its role in pathogen clearance, the available data raise the intriguing possibility that currently approved NK-1R antagonists, such as aprepitant, could be repurposed for use as a co-therapy to limit neuroinflammatory damage associated with infectious agents and certain neurodegenerative conditions. The use of such agents might have considerable advantages over other anti-inflammatory agents such as corticosteroids, non-steroidal anti-inflammatory drugs, prostaglandin inhibitors, and P2X7 antagonists, by limiting excessive inflammation without broadly attenuating host immune responses that may be required to resolve infection. Continued research on the ability of NK-1R antagonists to alleviate these health conditions may therefore yield new treatment options for patients with CNS infections, and perhaps other inflammatory neurological disorders.

**CONCLUDING REMARKS**

Infectious and sterile CNS disorders are often associated with overwhelming and damaging inflammation due to the immune responses of resident CNS cells and infiltrating leukocytes. Currently, neuroinflammatory diseases such as meningitis are treated with corticosteroids in combination with antibacterial, antiviral, or antifungal agents (Aberdein and Singer, 2006; Hoffman and Weber, 2009). Corticosteroids have both anti-inflammatory and immunosuppressive properties and treatment with these agents has been shown to reduce the risk of hearing loss and mortality due to meningitis. However, the immunosuppressive properties of corticosteroids may interfere with the ability of the body to clear infections, especially if the antibiotics used are not effective or antiviral medications are not available (Fitch and van de Beek, 2008). Furthermore, corticosteroid treatment can lead to adverse effects including the development of ulcers, myopathy, and bone loss, or central effects including sleep disorders and mood swings. As such, there is a current need for new treatment options to limit neuroinflammation associated with infection of the CNS and neurodegenerative conditions.

Substance P is produced at high levels in the CNS, and its target receptor NK-1R is expressed by resident CNS cells including microglial and astrocytes, and by immune cells that can infiltrate the CNS such as macrophages and lymphocytes. Importantly, this tachykinin functions both as a neurotransmitter and an immunomodulator, and substance P is recognized to exacerbate inflammatory responses at peripheral sites including the skin, lung and gastrointestinal and urogenital tracts. In infectious and sterile CNS conditions associated with severe neuroinflammation, substance P/NK-1R interactions appear to augment inflammation by increasing the release of inflammatory mediators while concomitantly decreasing the production of anti-inflammatory cytokines from microglia and astrocytes (as summarized in Figure 1) thereby exacerbating neuronal damage (Chauhan et al., 2008, 2011). Our own studies indicate that therapeutic intervention with NK-1R antagonists can limit neuroinflammation, reactive gliosis and demyelination in a mouse model of streptococcal meningitis (Chauhan et al., 2011) while other groups have shown efficacy of these agents in animal models of MS (Nessler et al., 2006; Reinke et al., 2006). This data therefore supports the use of NK-1R receptor antagonists in the treatment of such neuroinflammatory disorders.

The latest generation of NK-1R antagonists can be delivered orally and can readily cross the blood-brain barrier. Importantly, these antagonists exert central effects and the NK-1R antagonist, aprepitant, is approved for use as an anti-emetic agent in patients receiving chemotherapy. As such, the repurposing of currently available NK-1R antagonists may yield alternative co-therapy options for CNS inflammation associated with extracellular bacteria and parasites, and perhaps MS, with more specificity and reduced adverse effects.

**AUTHOR CONTRIBUTIONS**

All authors have contributed significantly to the preparation of this review article.

**FUNDING**

This work is supported by the NINDS (National Institutes of Health) research grant R01 NS050325 awarded to IM.
REFERENCES

Aapro, M., Carides, A., Rapoport, B. L., Schmol, H. J., Zhang, L., and Warr, D. (2015). Apprient and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20, 450–458. doi: 10.1634/theoncologist.2014-0229

Abbadie, C., Brown, J. L., Mantiy, P. W., and Basbaum, A. I. (1996). Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience 70, 201–209. doi: 10.1016/0306-4522(95)00343-h

Aberdein, J., and Singer, M. (2006). Clinical review: a systematic review of corticosteroid use in infections. Crit. Care 10:203. doi: 10.1186/cc3904

Agro, A., and Stanisz, A. M. (1993). Inhibition of murine intestinal inflammation by anti-substance P antibody. Reg. Immunol. 5, 120–126

Andoh, T., Nagasawa, T., and Kuraishi, Y. (1996). Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse. Brain Res. Mol. Brain Res. 35, 329–332. doi: 10.1016/0169-328x(95)00244-m

Arsenescu, R., Blum, A. M., Metwali, A., Elliott, D. E., and Weinstock, J. V. (2005). IL-12 induction of mRNA encoding substance P in murine macrophages from the spleen and sites of inflammation. J. Immunol. 174, 3906–3911. doi: 10.4049/jimmunol.174.7.3906

Baker, S. J., Morris, J. L., and Gibbins, I. L. (2003). Cloning of a C-terminally truncated NK1 receptor from guinea-pig nervous system. Brain Res. Mol. Brain Res. 111, 136–147. doi: 10.1016/s0169-328x(03)00002-0

Beaujouan, J. C., Teutsch, B., Saffroy, M., Petitet, F., Torrens, Y., and Glowiński, J. (1991). NK1 receptors are the only class of tachykinin receptors found on mouse cortical astrocytes. Peptides 12, 813–820. doi: 10.1016/0196-9781(91)90139-g

Beinborn, M., Blum, A., Hang, L., Setiawan, T., Schroeder, J. C., Stoyanoff, K., et al. (2010). TGF-β regulates T-cell neurokinin-1 receptor internalization and function. Proc. Natl. Acad. Sci. U S A 107, 4293–4298. doi: 10.1073/pnas.0905871010

Benaroch, E. E., Schmeichel, A. M., Low, P. A., and Parisi, J. E. (2003). Depletion of ventromedullary NK-1 receptor-immunoreactive neurons in multiple system atrophy. Brain 126, 2183–2190. doi: 10.1093/brain/awg230

Bergström, M., Hargreaves, R. J., Burns, H. D., Goldberg, M. R., Sciberras, D., Reines, S. A., et al. (2004). Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. J. Immunol. 173, 6107–6114. doi: 10.4049/jimmunol.173.9.6107

Bill, A., Stjernschantz, J., Mandahl, A., Brodin, E., and Nilsson, G. (1979). The distribution of substance P immunoreactive fibers in the rat central nervous system. Acta Physiol. Scand. 116, 3651–3656. doi: 10.1111/j.1748-1716.1979. tb06412.x

Blum, A. M., Metwali, A., Crawford, C., Li, J., Qadir, K., Elliott, D. E., et al. (2004). Interleukin 12 and antigen independently induce substance P receptor expression in T cells. J. Immunol. 173, 3598–3605. doi: 10.4049/jimmunol.173.7.3598

Bost, K. L., Breeding, S. A., and Pascual, D. W. (1992). Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS. Reg. Immunol. 4, 105–112

Bost, K. L., and Pascual, D. W. (1992). Substance P: a late-acting B lymphocyte differentiation cofactor. Am. J. Physiol. 262, C537–C545

Bradesi, S., Svensson, C. I., Steinauer, J., Pothoulakis, C., Yaks, T. L., and Mayer, E. A. (2009). Role of spinal microglia in visceral hyperalgesia and NK1R up-regulation in a rat model of chronic stress. Gastroenterology 136, 1339.e1–1348.e2. doi: 10.1053/j.gastro.2008.12.044

Brown, G. C., and Neher, J. I. (2010). Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 41, 242–247. doi: 10.1007/s12035-010-8105-9

Caberlotto, L., Hurd, Y. L., Murdock, P., Wahlin, J. P., Melotto, S., Corsi, M., et al. (2003). Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur. J. Neurosci. 17, 1736–1746. doi: 10.1046/j.1460-9568.2003.02600.x

Calvo, C. F., Chavanel, G., and Senik, A. (1992). Substance P enhances IL-2 expression in activated human T cells. J. Immunol. 148, 3498–3504

Castagliulo, I., Riegler, M., Pasha, A., Nikulasson, S., Lu, B., Gerard, C., et al. (1998). Neurokinin-1 (NK-1) receptor is required in Clostridium difficile–induced enteritis. J. Clin. Invest. 101, 1547–1550. doi: 10.1172/jci2039

Chauhan, V. S., Furr, S. R., Sterka, D. G. Jr., Nelson, D. A., Moeddyk-Schauwecker, M., Marriott, I., et al. (2010). Vascular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. Virology 400, 187–196. doi: 10.1016/j.virol.2010.01.025

Chauhan, V. S., Kutz, J. M., Bost, K. L., and Marriott, I. (2011). Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J. Immunol. 186, 7255–7263. doi: 10.4049/jimmunol.1100721

Chauhan, V. S., Sterka, D. G. Jr., Furr, S. R., Young, A. B., and Marriott, I. (2009). NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens. Glia 57, 414–423. doi: 10.1002/glia.20770

Chauhan, V. S., Sterka, D. G. Jr., Gray, D. L., Bost, K. L., and Marriott, I. (2008). Neurogenic macroactivation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J. Immunol. 180, 8241–8249. doi: 10.4049/jimmunol.180.12.8241

Chen, L. W., Yung, K. K., and Chan, Y. S. (2004). Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson’s disease. Curr. Drug Targets 5, 197–206. doi: 10.2174/1389450043490596

Chernova, I., Lai, J.-P., Li, H., Schwartz, L., Tuluc, F., Korchak, H. M., et al. (2009). Substance P (SP) enhances CL513-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J. Leukoc. Biol. 85, 154–164. doi: 10.1189/jlb.0408026

Corrigan, F., Vink, R., and Turner, R. J. (2016). Inflammation in acute CNS injury: a focus on the role of substance P. Br. J. Pharmacol. 173, 703–715. doi: 10.1111/bph.13155

Covas, M. J., Pinto, L. A., and Victorino, R. M. (1994). Disturbed immunoregulatory properties of the neuropeptide substance P on lymphocyte proliferation in HIV infection. Clin. Exp. Immunol. 96, 384–388. doi: 10.1111/j.1365-2449.1994.tb06059.x

Croitoru, K., Ernst, P. B., Bienenstein, J., Padol, I., and Stanisz, A. M. (1990). Selective modulation of the natural killer activity of murine intestinal intraepithelial leucocytes by the neuropeptide substance P. Immunology 71, 196–201

Cuello, A. C., Ribeiro-da-Silva, A., Ma, W., De Koninck, Y., and Henry, J. L. (1993). Organization of substance P primary sensory neurons: ultrastructural...
and physiological correlates. Regul. Pept. 46, 155–164. doi: 10.1016/0167-0115(93)90006-5

Cunningham, S., O’Doherty, C., Patterson, C., McDonnell, G., Hawkins, S., Marrou, M. G., et al. (2007). The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis. J. Neuroimmunol. 183, 208–213. doi: 10.1016/j.neuroimm.2006.11.002

DeFea, K. A., Zalevsky, J., Thoma, M. S., Déry, O., Mullins, R. D., and Bunnett, N. W. (2000). β-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell Biol. 148, 1267–1281. doi: 10.1083/jcb.148.6.1267

Di Fabio, R., Alvaro, G., Braggio, S., Carletti, R., Gerrard, P. A., Griffante, C., et al. (2013). Identification, biological characterization and pharmacological analysis of a new potent and selective NK1 receptor antagonist clinical candidate. Bioorg. Med. Chem. 21, 6264–6273. doi: 10.1016/j.bmc.2013.09.001

Douglas, S. D., Cnaan, A., Lynch, K. G., Benton, T., Zhao, H., Gettes, D. R., et al. (2008a). Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. AIDS Res. Hum. Retroviruses 24, 375–378. doi: 10.1089/aid.2007.0207

Douglas, S. D., Lai, J. P., Tuluc, F., Schwartz, L., and Kilpatrick, L. E. (2008b). Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis. Ann. N Y Acad. Sci. 1144, 90–96. doi: 10.1196/annals.1418.007

Douglas, S. D., Ho, W. Z., Gettes, D. R., Cnaan, A., Zhao, H., Leserman, J., et al. (2001). Elevated substance P levels in HIV-infected men. AIDS 15, 2043–2045. doi: 10.1097/00002030-200110190-00019

Douglas, S. D., and Leeman, S. E. (2011). Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann. N Y Acad. Sci. 1217, 83–95. doi: 10.1111/j.1749-6632.2010.05826.x

Doyle, C. A., and Hunt, S. P. (1999). Substance P receptor (NK-1R) via NF-κB upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-κB in astrocytes. Glia 48, 259–266. doi: 10.1002/glia.20079

Harrison, S., and Geppetti, P. (2001). Substance P. Int. J. Biochem. Cell Biol. 33, 555–556. doi: 10.1016/S1357-2725(01)00331-0

Hickey, W. F. (1999). Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol. 11, 125–137. doi: 10.1016/s0899-7088(99)90016-8

Hietala, J., Nyman, M. J., Eskola, O., Laakso, A., Grönroos, T., Oikonen, V., et al. (2005). Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol. Imaging Biol. 7, 262–272. doi: 10.1016/s1130-9055-17-01506-6

Ho, W. Z., Lai, J. P., Zhu, X. H., Uvaydova, M., and Douglas, S. D. (1997). Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J. Neuroimmunol. 71, 73–80. doi: 10.1016/S0165-5728(96)00324-0

Hocking, S., and Weber, R. J. (2009). Pathophysiology and treatment of bacterial meningitis. Ther. Adv. Neurol. Disorder. 2, 1–7. doi: 10.1175/175628650937975

Hökfelt, T., Keller, J. O., Nilsson, G., and Pernow, B. (1978). Substance P: localization in the central nervous system and in some primary sensory neurons. Science 190, 889–890. doi: 10.1126/science.242075

Holzer, P. (1998). Neurogenic vasodilatation and plasma leakage in the skin. Gen. Pharmacol. 30, 5–11. doi: 10.1016/s0306-3623(97)00078-5

Iyengar, S., Hipkind, P. A., Gehlert, D. R., Schober, D., Lubb, K. L., Nixon, J. A., et al. (1997). L7303870, a centrally active neurokinin-1 antagonist with a long duration of action. J. Pharmacol. Exp. Ther. 280, 774–785.

Kataeva, G., Agro, A., and Stanisz, A. M. (1994). Substance-P-mediated hyperalgesia is enhanced in substance P receptor-deficient mice infected with murine gammaherpesvirus 68. J. Immunol. 170, 2605–2612. doi: 10.4049/jimmunol.170.5.2605

Kitch, M. T., and van de Beek, D. (2008). Drug Insight: steroids in CNS infectious disease—new indications for an old therapy. Nat. Clin. Pract. Neurol. 4, 97–104. doi: 10.1038/ncpneurol0713

Fong, T. M., Anderson, S. A., Yu, H., Huang, R. R., and Strader, C. D. (1992). Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol. Pharmacol. 41, 24–30.

Garca-Recio, S., and Gascón, P. (2015). Biological and pharmacological aspects of the NK1-receptor. Biomed. Res. Int. 2015:495704. doi: 10.1155/2015/495704

Garza, A., Tewardy, D. J., Weinstock, J., Viswanathan, B., and Robinson, P. (2010). Substance P signaling contributes to granuloma formation in Taenia crassiceps infection, a murine model of cystercerosis. J. Biomed. Biotechnol. 2010:597086. doi: 10.1155/2010/597086

Garza, A., Weinstock, J., and Robinson, P. (2008). Absence of the SP/SP receptor circuitry in the substance P-precursor knockout mice or SP receptor, neurokinin (NK1) knockout mice leads to an inhibited cytokine response in granulomas associated with murine Taenia crassiceps infection. J. Parasitol. 94, 1253–1258. doi: 10.1645/ge-1481.1

Gerard, N. P., Garraway, L. A., Eddy, R. L. Jr., Shows, T. B., Iijima, H., Paquet, J. L., et al. (1991). Human substance P receptor (NK-1): organization of the gene, chromosomal localization and functional expression of cDNA clones. Biochemistry 30, 10640–10646. doi: 10.1021/bi00108a006

Gillespie, E., Leeman, S. E., Watts, L. A., Coukos, J. A., O’Brien, M. J., Cerda, S. R., et al. (2011). Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc. Natl. Acad. Sci. U S A 108, 17420–17425. doi: 10.1073/pnas.1114275108

Goode, T., O’Connor, T., Hopkins, A., Moriarty, D., O’Sullivan, G. C., Collins, J. K., et al. (2003). Neurokinin-1 receptor (NK-1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P. J. Cell. Physiol. 197, 30–41. doi: 10.1002/jcp.10234

Guo, C. I., Douglas, S. D., Gao, Z., Wolf, B. A., Grinspan, J., Lai, J. P., et al. (2004). Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-κB in astrocytes. Glia 48, 259–266. doi: 10.1002/glia.20079

Kowall, N. W., Quigley, B. J. Jr., Krause, J. E., Lu, F., Kosofsky, B. E., and Ferrante, R. J. (1993). Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul. Pept. 46, 174–185. doi: 10.1016/0167-0115(93)90028-7
Johnson et al. Targeting NK-1R to Limit Neuroinflammation

Kramer, M. S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J. J., et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640–1645. doi: 10.1126/science.281.5383.1640

Kroegel, C., Gienbrycz, M. A., and Barnes, P. J. (1990). Characterization of eosinophil cell activation by peptides. Differential effects of substance P, melittin and FMET-Leu-Phe. J. Immunol. 145, 2581–2587.

Lai, J. P., Douglas, S. D., and Ho, W. Z. (1998). Human lymphocytes express substance P and its receptor. J. Neuroimmunol. 86, 80–86. doi: 10.1016/s0165-5728(98)00023-3

Lai, J. P., Ho, W. Z., Yang, J. H., Wang, X., Song, L., and Douglas, S. D. (2002). A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes. J. Neuroimmunol. 128, 101–108. doi: 10.1016/s0165-5728(02)00164-9

Lai, J. P., Ho, W. Z., Zhan, G. X., Yi, Y., Collin, R. G., and Douglas, S. D. (2001). Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc. Natl. Acad. Sci. U. S. A 98, 3970–3975. doi: 10.1073/pnas.071052298

Lai, J. P., Lai, S., Tuluc, F., Tanksy, M. F., Kilpatrick, L. E., Leeman, S. E., et al. (2008). Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc. Natl. Acad. Sci. U. S. A 105, 12605–12610. doi: 10.1073/pnas.0806632105

Maggi, C. A. (1995). The mammalian tachykinin receptors.

Maggi, C. A. (1997). The effects of tachykinins on inflammatory and immune cells. Inflamm. Allergy Proc. 18, 535–564.

Lotz, M., Vaughan, J. H., and Carson, D. A. (1985). Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production. Glia 21, 183–193. doi: 10.1002/glia.440210202

Lubrano, J., Siegel, J., and Leeman, S. E. (1994). Substance P enhances the secretion of tumor necrosis factor-alpha from neuronal cells stimulated with lipopolysaccharide. J. Immunol. 152, 819–824.

Maggi, C. A. (1995). The mammalian tachykinin receptors. Gen. Pharmacol. 26, 911–944. doi: 10.1016/0306-3623(94)00292-U

Maggi, C. A. (1997). The effects of tachykinins on inflammatory and immune cells. Regul. Pept. 70, 75–90. doi: 10.1016/s0167-0115(97)90029-3

Manak, M. M., Moshkoff, D. A., Nguyen, L. T., Meshki, J., Tebas, P., Tuluc, F., et al. (2010). Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprapetin and synergistic interactions with other antiretrovirals. AIDS 24, 2789–2796. doi: 10.1097/QAD.0b013e3283405e33

Mantyh, P. W. (2002). Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiatry 63, 6–10.

Mantyh, P. W., Gates, T., Mantyh, C. R., and Maggio, J. E. (1989). Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues. J. Neurosci. 9, 258–279.

Mantyh, P. W., Hunt, S. P., and Maggio, J. E. (1984). Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioguid. Brain Res. 307, 147–165. doi: 10.1016/0006-8993(84)90470-0

Marriott, I., and Bost, K. L. (2001b). Substance P receptor mediated macrophage responses. Adv. Exp. Med. Biol. 493, 247–254. doi: 10.1007/0-306-47611-8_30

Marriott, I., and Wilkin, G. P. (1993). Substance P receptors on O-2A progenitor cells and type-2 astrocytes in vitro. J. Neurochem. 61, 826–834. doi: 10.1111/j.1471-4159.1993.tb0359x

Mazumdar, S., and Das, K. M. (1992). Immunocytochemical localization of vasointestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am. J. Gastroenterol. 87, 176–181.

Michel, J. P., Sakamoto, N., Bouvier, R., Tommassi, M., and Pearson, J. (1986). Substance P-immunoreactive astrocytes related to deep white matter and striatal blood vessels in human brain. Brain Res. 377, 383–387. doi: 10.1016/0006-8993(86)90886-3

Mondal, D., Stadelmann, C., Bittner, A., Schlegel, K., Gronen, F., Brucke, W., et al. (2006). Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist—a putative role for substance P in CNS inflammation. J. Neuroimmunol. 179, 1–8. doi: 10.1016/j.jneuroim.2006.06.026

O’Connor, T. M., O’Connell, J., O’Brien, D. I., Goode, T., Bredin, C. P., and Shanahan, F. (2004). The role of substance P in inflammatory disease. J. Cell. Physiol. 201, 167–180. doi: 10.1002/jcp.1003470208

Padua, D., Yu, J. P., Germano, P. M., and Pisegna, J. R. (2016). The role of neuropeptides in mouse models of colitis. J. Mol. Neurosci. 59, 203–210. doi: 10.1007/s12031-015-0688-1

Palma, C., and Manzini, S. (1998). Substance P induces secretion of immunomodulatory cytokines by human astrocytoma cells. J. Neuroimmunol. 81, 127–137. doi: 10.1016/s0165-5728(97)00167-7

Palma, C., Minghetti, L., Astolfi, M., Ambrosini, E., Silberstein, F. C., Manzini, S., et al. (1997). Functional characterization of substance P receptors on cultured human spinal cord astrocytes: synergism of substance P with cytokines in inducing interleukin-6 and prostat glandlin E2 production. J. Neuroimmunol. 81, 273–281. doi: 10.1016/s0165-5728(97)00167-7

Pascual, D. W., Xu-Amano, J. C., Kiyono, H., McGhee, J. R., and Bost, K. L. (2011a). Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. J. Immunol. 187, 3970–3975. doi: 10.1111/j.1752-4841.2011.00164.x

Pernow, B. (1983). Substance P.
Quartara, L., and Altamura, M. (2006). Tachykinin receptors antagonists: from research to clinic. Curr. Drug Targets 7, 975–992. doi: 10.2174/138945006778019381

Quartara, L., Altamura, M., Evangelista, S., and Maggi, C. A. (2009). Tachykinin receptor antagonists in clinical trials. Expert. Opin. Investig. Drugs 18, 1843–1864. doi: 10.1517/135437809379530

Quigley, B. J. Jr., and Kowall, N. W. (1991). Substance P-like immunoreactive neurons are depleted in Alzheimer’s disease cerebral cortex. Neuroscience 41, 41–60. doi: 10.1016/0366-4543(91)90199-x

Raffa, R. B. (1998). Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Neurosci. Biobehav. Rev. 22, 789–813. doi: 10.1016/s0149-7634(97)00070-5

Rasley, A., Anguita, J., and Marriott, I. (2002a). Borrelia burgdorferi induces inflammatory mediator production by murine microglia. J. Neuroimmunol. 130, 22–31. doi: 10.1016/s0165-5728(02)01087-x

Rasley, A., Bost, K. L., Olson, J. K., Miller, S. D., and Marriott, I. (2002b). Expression of functional NK-1 receptors in murine microglia. Glia 37, 258–267. doi: 10.1002/glia.10034

Rasley, A., Bost, K. L., and Marriott, I. (2004a). Murine gammaherpesvirus-68 elicits robust levels of interleukin-12 p40 but not interleukin-12 p70 production, by murine microglia and astrocytes. J. Neurovirol. 10, 171–180. doi: 10.1080/13894500490444119

Reinke, E. K., Johnson, M. J., Ling, C., Karman, J., Lee, J., Weinstock, J. V., et al. (2003a). Substance P is required for the pathogenesis of EMCV infection in mice. J. Clin. Exp. Med. 19, 219–227. doi: 10.1097/01.jem.00001365-013-0166-x

Satake, H., and Kawada, T. (2006). Overview of the primary structure, tissue-distribution and functions of tachykinins and their receptors. Curr. Drug Targets 7, 963–974. doi: 10.2174/13894500678019273

Scharff, M., Beiter, T., Becker, H. D., and Hunt, T. K. (1998). Neuropeptides: mediators of inflammation and tissue repair? Arch. Surg. 133, 1077–1116. doi: 10.1001/archsurg.133.10.1107

Schwartz, L., Spitsin, S. V., Meshki, J., Tuluc, F., Douglas, S. D., and Wolfe, J. H. (2013). Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor. J. Neurovirol. 19, 219–227. doi: 10.1080/13894500678019273

Severini, C., Impota, G., Falconieri-Erspamer, G., Salvadori, S., and Erspamer, V. (2002). The tachykinin peptide family. Pharmacol. Rev. 54, 285–322. doi: 10.1124/pr.54.2.285

Stumm, R., Culmsee, C., Schafer, M. K., Kriegstein, J., and Weibe, E. (2001). Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J. Neurosci. 21, 798–811.

Sun, J., Ramnath, R. D., Zhi, L., Tamizhselvi, R., and Bhatia, M. (2008). Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am. J. Physiol. Cell Physiol. 294, C1586–C1596. doi: 10.1152/ajpcell.00133.2008

Swain, M. G., Agro, A., Blemmerhassett, P., Stanisz, A., and Collins, S. M. (1992). Increased levels of substance P in the myenteric plexus of Trichinella-infected rats. Gastroenterology 102, 1913–1919. doi: 10.1016/0002-5858(92)90313-n

Taikasin, K., Tanaka, A., Hara, M., and Nakasibi, S. (1992). The primary structure and gene organization of human substance P and neuropekin receptor receptors. Eur. J. Biochem. 204, 1025–1033. doi: 10.1111/j.1432-1033.1992.tb6724.x

Taupin, P. (2008). Alzheimer’s disease, aneuploidy and neurogenesis. Med. Sci. Monit. 14, L6–L6.

Torrens, Y., Daguet De Montusty, M. C., et al., M. E., Bejuouan, J. C., and Glowiński, I. (1989). Tachykinin receptors of the NK1 type (substance P) coupled positively to phospholipase C on cortical astrocytes from the newborn mouse in primary culture. J. Neurochem. 52, 1913–1918. doi: 10.1111/j.1471-4158.1999.tb07276.x

Vandenbroeck, K., Fiten, P., Heggarty, S., Goris, A., Cocco, E., Hawkins, S. A., et al. (2002). Chromosome 7q21–22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. J. Neuroimmunol. 125, 141–148. doi: 10.1016/s0165-5728(02)00032-1

Van Hinsberg, V. W., and van Nieuw Amerongen, G. P. (2002). Endothelial hypermeability in vascular leakage. Vascul. Pharmacol. 39, 171–172. doi: 10.1016/s0378-5122(02)00027-8

V-Euler, U. S., and Gaddum, J. H. (1931). An unidentified depressor substance in certain tissue extracts. J. Physiol. 72, 74–87. doi: 10.1113/jphysiol.1931.sp002763

Vilisaar, J., Kivame, K., Braitch, M., Aram, J., Furtyn, F., Fahey, A. J., et al. (2015). Reciprocal regulation of substance P and IL-12/IL-23 and the associated cytokines, IFNγ/IL-17: a perspective on the relevance of this interaction to multiple sclerosis. J. Neuroimmune Pharmacol. 10, 457–467. doi: 10.1007/s11481-015-9589-x

Water, R. G., and Davis, T. P. (1997). Alterations of peptide metabolism and neuropoiesis in senile dementia of the Alzheimer’s type. Ann. N Y Acad. Sci. 814, 30–39. doi: 10.1111/j.1749-6632.1997.tb46142.x

Weinstock, J. V., Blum, A., Metwali, A., Elliott, D., and Arsenescu, R. (2003a). IL-18 and IL-12 signal through the NF-kappaB pathway to induce NK-1R expression on T cells. J. Immunol. 170, 5003–5007. doi: 10.4049/jimmunol.170.10.5003

Weinstock, J. V., Blum, A., Metwali, A., Elliott, D., and Arsenescu, R. (2003b). Substance P regulates Th1-type colitis in IL-10 knockout mice. J. Immunol. 171, 3762–3767. doi: 10.4049/jimmunol.171.7.3762

Serra, M. C., Bazzoni, F., Della Bianca, V., Geskowiski, M., and Rossi, F. (1988). Activation of human neutrophils by substance P. Effect on oxidative metabolism, exocytosis, cytosolic Ca2+ concentration and inositol phosphate formation. J. Immunol. 141, 2118–2124.
Whitney, N. P., Eidem, T. M., Peng, H., Huang, Y., and Zheng, J. C. (2009). Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J. Neurochem. 108, 1343–1359. doi: 10.1111/j.1471-4159.2009.05886.x

Zhu, J., Qu, C., Lu, X., and Zhang, S. (2014). Activation of microglia by histamine and substance P. Cell. Physiol. Biochem. 34, 768–780. doi: 10.1159/000363041

Ziebell, J. M., and Morganti-Kossmann, M. C. (2010). Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 7, 22–30. doi: 10.1016/j.nurt.2009.10.016

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2017 Johnson, Young and Marriott. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*